Ascletis Pharma Inc.
1672
Classement en actions
#10472
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Prix de l'action
$0.74836845
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$785.53M
Changement (1 jour)
1.12%
Changement (1 an)
-38.66%
Pays
CN
Échange Ascletis Pharma Inc. (1672)
Catégorie
Healthcare
Capitalisation boursière de Ascletis Pharma Inc.(1672)
Capitalisation boursière: $785.53M
En October 2026, Ascletis Pharma Inc. a une capitalisation boursière de $785.53M. Cela fait de Ascletis Pharma Inc. la 10472nd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Ascletis Pharma Inc. du 2019 au 2026
1672 par rapport au top 5 des plus populaires stocks
